Human Microbiome Therapeutics Market Size Worth $2,531.55 Million by 2029 | CAGR: 23.7%

The global human microbiome therapeutics market size is expected to reach USD 2,531.55 million by 2029 according to a new study by Polaris Market Research. The report “Human Microbiome Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Product (Probiotics, Prebiotics, Medical Foods, Prescription Drugs); By Therapeutic Area; By Indication; By Approach; By Region; Segment Forecast, 2022 - 2029” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Growing attention on microbiome-based initial illness detection, a rise in the incidence of diseases caused by dysbiosis, rising partnerships, and well-funded govt study programs are driving the global market. The Million Microbiome of Humans Project was founded in November 2019 to collaborate in the meta-genomic study with China, Denmark, France, Latvia, China, Sweden, as well as other nations.

The practicality of examining the complete human microbiome treatments has grown thanks to technological breakthroughs in next genomics as well as metagenomics. These breakthroughs have allowed scientists to cultivate the isolate anaerobes, individual microbiota and identify them.

Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/human-microbiome-therapeutics-market/request-for-sample

Because of the rise in nutritional additive use, the North American industry for such individual treatments is expected to lead worldwide. Furthermore, highly modern testing facilities for the manufacture of novel therapies, the existence of a health-conscious society, and rising healthcare investment are the key reasons for the area's dominance.

Key market players operating in the market are 4D Pharma PLC, 16S Technologies, 5QBD-Biotech, Biotagenics, BiomX, BoobyBiome, ClearB Therapeutics, Carbiotix, CoreBiome, DermBiont, Embion Technologies, E.I. du Pont de Nemours and Company, Enterome Bioscience, Exeliom Biosciences, Evelo Biosciences, Ferring Pharmaceuticals, Finch Therapeutics, GoodBelly, GoodGut, GNUbiotics Sciences, Holobiome, Hyggut, Commense, Igen Biolab Group, LNC Therapeutics., Lactobio, Oxidien Pharmaceuticals, LLC, Second Genome, Synlogic, UBiome, Seres Therapeutics, Vedanta Biosciences, and ViThera Pharmaceuticals.

Polaris Market Research has segmented the human microbiome therapeutics market report on the basis of product, therapeutic areas, indication, approach, and region:

Human Microbiome Therapeutics, Product Outlook (Revenue - USD Million, 2017 - 2029)

• Probiotics
• Medical Foods
• Prescription Drugs

Human Microbiome Therapeutics, Therapeutic Areas Outlook (Revenue - USD Million, 2017 - 2029)

• Autoimmune Disorders
• Dental Disorders
• Digestive and Gastrointestinal Disorders
• Dermatological Disorders
• Infectious Disease
• Metabolic Disorders
• Oncology
• Others

Human Microbiome Therapeutics, Indication Outlook (Revenue - USD Million, 2017 - 2029)

• Acne Vulgaris
• Atopic Dermatitis
• Clostridium difficile Infection
• Colorectal Cancer
• Diabetes
• Inflammatory Bowel Disease (IBD)
• Lactose Intolerance
• Lung Cancer
• Non-alcoholic steatohepatitis (NASH)
• Obesity
• Coeliac Disease

Human Microbiome Therapeutics, Approach Outlook (Revenue - USD Million, 2017 - 2029)

• Small Molecule Therapies
• Single Strain Whole Bacteria
• Microbial Consortia
• Genetically Modified Single Strain Bacteria
• Phage Cocktail
• Microbial Ecosystems

Human Microbiome Therapeutics, Regional Outlook (Revenue - USD Million, 2017 - 2029)

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Austria
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Indonesia
  • Malaysia
  • South Korea
• Latin America
  • Brazil
  • Argentina
  • Mexico
• Middle East & Africa
  • Israel
  • Saudi Arabia
  • South Africa
  • UAE